Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Research analysts at SunTrust Banks lowered their FY2020 earnings per share (EPS) estimates for Catalyst Pharmaceuticals in a note issued to investors on Thursday. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of $0.01 per share for the year, down from their previous forecast of $0.05. SunTrust Banks currently has a “Buy” rating and a $5.00 target price on the stock. SunTrust Banks also issued estimates for Catalyst Pharmaceuticals’ FY2021 earnings at $0.51 EPS.
Several other analysts have also recently weighed in on CPRX. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. Zacks Investment Research upgraded Catalyst Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Finally, Piper Jaffray Companies set a $6.00 target price on Catalyst Pharmaceuticals and gave the company a “buy” rating in a report on Monday, August 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Catalyst Pharmaceuticals presently has an average rating of “Buy” and an average target price of $5.50.
Shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) traded down $0.12 during midday trading on Monday, reaching $2.87. The company’s stock had a trading volume of 2,011,700 shares, compared to its average volume of 872,389. Catalyst Pharmaceuticals has a 12-month low of $1.01 and a 12-month high of $3.24.
Several large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Catalyst Pharmaceuticals by 11.3% during the second quarter. Vanguard Group Inc. now owns 3,348,549 shares of the biopharmaceutical company’s stock worth $9,242,000 after purchasing an additional 340,614 shares during the period. JPMorgan Chase & Co. raised its position in Catalyst Pharmaceuticals by 1,833.2% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,536,300 shares of the biopharmaceutical company’s stock valued at $4,240,000 after buying an additional 1,456,830 shares during the last quarter. State Street Corp raised its position in Catalyst Pharmaceuticals by 1,971.1% in the 2nd quarter. State Street Corp now owns 938,195 shares of the biopharmaceutical company’s stock valued at $2,590,000 after buying an additional 892,895 shares during the last quarter. Kennedy Capital Management Inc. raised its position in Catalyst Pharmaceuticals by 298.5% in the 2nd quarter. Kennedy Capital Management Inc. now owns 918,438 shares of the biopharmaceutical company’s stock valued at $2,535,000 after buying an additional 687,938 shares during the last quarter. Finally, Northern Trust Corp raised its position in Catalyst Pharmaceuticals by 620.9% in the 2nd quarter. Northern Trust Corp now owns 802,566 shares of the biopharmaceutical company’s stock valued at $2,215,000 after buying an additional 691,238 shares during the last quarter. 40.19% of the stock is currently owned by institutional investors.
In other news, insider Patrick J. Mcenany bought 20,000 shares of the stock in a transaction dated Tuesday, September 5th. The shares were bought at an average cost of $2.58 per share, with a total value of $51,600.00. Following the completion of the transaction, the insider now directly owns 4,471,026 shares of the company’s stock, valued at $11,535,247.08. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 8.79% of the stock is owned by corporate insiders.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.